US biopharma SAB Biotherapeutics (Nasdaq: SABS) has received both Breakthrough and Fast Track designations for SAB-176 from the US Food and Drug Administration (FDA) in the past week.
SAB-176 is the company’s investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.
News of the Breakthrough Designation led shares in the firm to close 38% higher on Tuesday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze